Rights statement: This is the version of record of the following protocolMalhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA, Chhetri SK, Mulvaney CA, Villanueva G. Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD013945. DOI: 10.1002/14651858.CD013945. Accessed 12 September 2022 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013945/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Final published version, 165 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
| Article number | CD013945 |
|---|---|
| <mark>Journal publication date</mark> | 24/06/2022 |
| <mark>Journal</mark> | Cochrane Database of Systematic Reviews |
| Issue number | 6 |
| Volume | 2022 |
| Number of pages | 12 |
| Publication Status | Published |
| <mark>Original language</mark> | English |
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the efficacy and harms or adverse events of immunomodulatory therapies in people with ALS compared with a placebo, no additional treatment, or a standard-of-care protocol (with or without riluzole, edaravone, or both).